Ironveld (LON: IRON) says its DMS plant has entered sustained production over 16 hours each day. Production is consistently producing 1.4tph of DMS grade magnetite product and 1tph of Maghemite, which is used in drilling muds. By the end of July, the plant could be reaching capacity of 5tph of magnetite. Three customers have been secured and there is strong demand for the product. The share price rebounded 29% to 0.0245p.
Increased interest in oil and gas exploration has boosted revenues of Getech Group (LON: GTC) and help it move towards profitability. Interim revenues were 15% ahead at £2.4m. Annualised costs have been reduced by £1m. Annualised recurring revenues were maintained at £2.8m. The company is expected to breakeven this year. The share price increased 12.8% to 2.2p.
Agronomics (LON: ANIC) executive chair Jim Mellon has acquired 27.49 million shares from BlueNalu Inc at 5.43p each and he has a right of first refusal over a further 3.15 million shares until 1 October 2026. This stops the shares being sold in the market. Agronomics has a 13% stake in BlueNalu. During March, Jim Mellon had bought 6.05 million shares that were not previously reported. Agronomics had NAV of 12.93p/share at the end of June 2026. The share price rose 4% to 5.2p.
SysGroup (LON: SYS) executive chairman has bought 416,639 shares at 24p each. He owns 13.2% of the managed IT services provider. The share price improved 6.25% to 25.5p.
FALLERS
Shares in oil and gas producer Angus Energy (LON: ANGS) returned from suspension down 22.9% to 0.185p. This follows the general meeting where shareholders gave approval to complete the financial restructuring and £3m fundraising at 0.2p/share. Ross Pearson has been appointed an executive director.
Cancer immunotherapy company Poolbeg Pharma (LON: POLB) is raising £3.75m at 6p/share, including £250,000 subscribed by executive chair Cathal Friel. The cash will fund the business while the POLB 001 TOPICAL trial, where the first patient has been dosed, and the Oral GLP-1 proof-of-concept trial while ongoing partnering discussions continue. The cash should last until the second quarter of 2028. Oak Securities has been appointed joint broker of Poolbeg Pharma. The share price declined 12.9% to 6.1p.
Rock Resources (LON: ROCK) says hole HMO-018 at the Molaoi zinc deposit in Greece has intersected good zinc grades. This drilling will upgrade the inferred resource to an indicated resource. Drilling continues and results from HMO-019 and HMO-020 are awaited. The share price slipped 7.26% to 0.115p.
Healthcare communications technology provider Feedback (LON: FDBK) reported a dip in full year revenues to around £800,000, but the EBITDA loss will be lower than expected. The pre-tax loss declined from £7.3m to £3.5m. Cash was £2.7m at the end of May 2026. This should last until the middle of 2027. NHS decision making remains frustratingly slow, but more GP practices are signing up for the Bleepa technology. The share price fell 4.44% to 6.45p.